1Alves DW, Kennedy MT.Community acquired pneumonia in casualty etiology clinical features diagnosis and man- agement (or a look at the "new" in pneumonia since 2002 )[J].Curr Opin Pulm Med,2004,10( 3 ) : 166.
5Battleman DS, Callahan M, Thaler HT.Rapid antibiotic de- livery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource uti- lization[J]. Arch Intern Med, 2002,162(6) :682.
6Castro GA, Viejo RA, Soler SS, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial[J]. Am J Med, 2001,111(5):367.
7Huchon G J, Gialdroni-Grassi G, Leophonte P, et al. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey[J]. Eur Respir J, 1996,9(8) : 1 590.
6Zacher L Gates RH 等.社区获得性肺炎.美国最新临床医学问答-感染性疾病[M].北京:海洋出版社,2000.431-439.
7Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
9Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
10Food and Drug Administration,HHS.Class Ⅱ Special Controls Guidance Document:serological assays for the detection of betaglucan.Fed Reqist,2004,69:56934-56936.
